We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
CALL
Eli Lilly
LLY
$1.09T
$174M 10.13%
23,675
-5,672
-19% -$422K
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$134M 7.8%
6,000
-8,000
-57% -$1.75M
OEF icon
3
PUT
iShares S&P 100 ETF
OEF
$19.8B
$100M 5.82%
7,419
-7,473
-50% -$725K
REGN icon
4
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
$80.7M 4.69%
2,198
+406
+23% +$154K
MRK icon
5
CALL
Merck
MRK
$326B
$74.5M 4.33%
13,255
+8,553
+182% +$501K
REGN icon
6
Regeneron Pharmaceuticals
REGN
$72.9B
$59.7M 3.47%
162,517
+86,598
+114% +$32.9M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.63B
$55.3M 3.22%
2,014,787
+1,478,505
+276% +$59.4M
AMGN icon
8
PUT
Amgen
AMGN
$212B
$54M 3.14%
3,694
+1,125
+44% +$169K
SRPT icon
9
PUT
Sarepta Therapeutics
SRPT
$1.63B
$52.8M 3.07%
19,251
-7,497
-28% -$301K
BMY icon
10
PUT
Bristol-Myers Squibb
BMY
$130B
$49.5M 2.88%
8,478
+5,009
+144% +$274K
HCA icon
11
CALL
HCA Healthcare
HCA
$92.8B
$48M 2.8%
6,491
-1,189
-15% -$89K
AMGN icon
12
Amgen
AMGN
$212B
$37M 2.15%
252,795
+119,619
+90% +$18M
BMY icon
13
CALL
Bristol-Myers Squibb
BMY
$130B
$31.7M 1.84%
5,419
+10
+0.2% +$547
TEVA icon
14
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$31.3M 1.82%
+8,638
New +$345K
GILD icon
15
CALL
Gilead Sciences
GILD
$167B
$30.9M 1.8%
4,317
-7,374
-63% -$548K
LLY icon
16
PUT
Eli Lilly
LLY
$1.09T
$29.7M 1.73%
4,043
-855
-17% -$63.7K
XNTK icon
17
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$27.4M 1.59%
4,623
+2,665
+136% +$160K
TSRO
18
CALL
DELISTED
TESARO, Inc.
TSRO
$25.1M 1.46%
1,866
+1,533
+460% +$193K
ESRX
19
CALL
DELISTED
Express Scripts Holding Company
ESRX
$19.9M 1.16%
2,897
– –
ALXN
20
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$19.4M 1.13%
+1,586
New +$194K
ACAD icon
21
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
$18.7M 1.09%
+6,470
New +$171K
BMY icon
22
Bristol-Myers Squibb
BMY
$130B
$16.9M 0.98%
289,183
+132,296
+84% +$7.23M
VTRS icon
23
CALL
Viatris
VTRS
$20.8B
$15.9M 0.92%
4,162
+1,358
+48% +$50.5K
UTHR icon
24
PUT
United Therapeutics
UTHR
$26.1B
$15.8M 0.92%
1,100
+2
+0.2% +$255
LLY icon
25
Eli Lilly
LLY
$1.09T
$15.7M 0.91%
+213,113
New +$15.9M
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.